Tuberculosis drug company TB Alliance revealed on Tuesday the addition of Jan Lundberg to its board of directors.
Dr Lundberg spent eight years as president of Lilly Research Laboratories and executive vice president of Science and Technology at Eli Lilly and Company.
Previously at AstraZeneca, Dr Lundberg was the global head of discovery research, including for infectious diseases and a TB Research facility in Bangalore.
Currently, Dr Lundberg is the cofounder of Aerocrine AB, a board member at Ardelyx, Betagenon and Image Analysis Group, a professor in the Department of Pharmacology at Karolinska Institute in Stockholm as well as a member of several governmental committees in both the EU and the US.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer